The Government negotiates and the ANMAT gathers data on the Johnson & Johnson vaccine, which the US stopped due to the appearance of clots

04/13/2021 11:02

• Clarín.com

• Society

Updated 04/13/2021 11:02 AM

The United States health authorities recommended that the use of the

Johnson & Johnson

vaccine

against the coronavirus be stopped to investigate if it causes the formation of blood clots.

They announced that they were investigating

six cases of patients

who suffered them after being vaccinated.

This vaccine

was tested in our country

on thousands of volunteers and the Government has already begun negotiating to buy millions of doses.

But

the Anmat had not yet approved the formula

and had requested more studies on its safety.

The

City had also shown interest

in purchasing this vaccine on its own.

Given the shortage of doses in the country and the global production crisis, one of the most anticipated vaccines to meet the global immunization demand is now in doubt.

The Johnson & Johnson vaccine needs

a single dose

to complete the level of defense against COVID.

It is worth clarifying that the mechanism is similar in all the acquisition of vaccines.

First it is negotiated with the laboratories, in this case,

Janssen,

which produces it, and then comes the emergency approval by the National Administration of Drugs, Food and Medical Technology (Anmat). 

According to the analysis of the results in Phase 2, it is

first approved for those under 59 years of age and then authorized for those over 60

.

The same happened with the Sputnik V, the Sinopharm and the Astrazeneca.

The United States suspended the application of the Johnson & Jhonson vaccine and is investigating the appearance of clots in people who have already received their doses.

This latest vaccine - the Oxford University formula that is produced in Korea and India - was also flagged for a dangerous side effect,

thrombosis.

But it was finally determined that it is a very rare reaction, which would be in one person in 100,000. 

The case of the Johnson & Johnson vaccine is different

.

Due to this recommendation from the Center for Disease Controls (CDC) and the Food and Drug Administration (FDA), federal distribution channels in the United States - including mass vaccination centers - will suspend the use of the J&J vaccine., As reported by a health official to CNN.

States and other providers are expected to follow suit. 

Last Tuesday, the Minister of Health, Carla Vizzotti, responded to the Commission for Social Action and Public Health of the Chamber of Deputies and said that it was in

dialogue with the American emporium Johnson & Johnson

for its Janssen vaccine, which is made up of only a dose.

Through a statement, Johnson & Johnson said it was aware that blood clots had been reported with some COVID-19 vaccines, but that "

no clear causal relationship has been established

between these rare events" and their injection.

All

patients were women, between 18 and 48 years old.

One of them died and another, in Nebraska, had to be hospitalized in critical condition.

More than

6.8 million doses

of the J&J vaccine

have been administered

in the United States.

CDC's Advisory Committee on Immunization Practices will meet Wednesday to review the cases.

The FDA has also launched an investigation.

The case of Astrazeneca

An investigation explained the cause of thrombosis after vaccination with

Astrazeneca.

The important thing to know is that they are

very rare conditions

that occurred with this vaccine.

They are linked to the appearance of unusual antibodies that activate platelets in the blood.

And what

happens in one every 100,000 vaccinated.

No cases of thrombosis were recorded among vaccinated people

in Argentina.

The precise reason for these rare reactions to the vaccine remains a mystery.

Scientific teams from Germany and Norway discovered that people who developed thrombosis after vaccination had produced

antibodies that activated their platelets

, a component of blood that is involved in clotting.

The new reports add extensive detail to what researchers have already publicly stated about this blood disorder.

Younger people seem more susceptible than older people, but the researchers say there is no known pre-existing health problem that predisposes people to this unusual reaction.

That is concerning, they say, because

there is no way to know if an individual is at high risk.

Reports of thrombosis have already led several countries to

limit the AstraZeneca vaccine

to older people or to stop using it altogether.

These cases have dealt a severe blow to global efforts to stop the pandemic, as AstraZeneca's vaccine - easy to store and relatively inexpensive - was a mainstay of vaccination programs in more than 100 countries.

SC

Look also

AstraZeneca Vaccine: Research Explains Cause of Thrombosis Cases

Coronavirus: Stamboulian seeks to buy 700 thousand vaccines from Pfizer or Moderna and a prepaid started contacts